Special Issue "Hyponatremia: Advances in Diagnosis and Management"
Deadline for manuscript submissions: closed (31 July 2014)
Prof. Dr. Lewis S. Blevins
California Center for Pituitary Disorders, University of California, San Francisco, 400 Parnassus Ave., A-808, San Francisco, California 94143-0350, USA
Website | E-Mail
Interests: pituitary tumors; hypopituitarism; acromegaly; prolactinoma; transsphenoidal pituitary surgery
Advances in molecular in cell biology have led to important discoveries leading to new therapies in all fields of medicine. This is particularly true in the story of the syndrome of inappropriate anti-diuresis (SIADH), wherein the cloning of the vasopressin receptor has led to drug development for the treatment of euvolemic and hypervolemic hyponatremia, disorders that have been recognized since the advent of accurate and reliable laboratory determinations of the serum sodium. Evaluation and management of patients with hyponatremia has always been based on clinical judgment and is subject to individual interpretation of findings in the clinical context of presentation and recent treatments. Therapies for hyponatremia, including fluid restriction, saline and lasix, 3% saline, and demeclocycline are less than ideal, poorly understood, and often ineffective. Development of a class of drugs known as the vaptans has revolutionized the treatment of euvolemic and hypervolemic hyponatremia.
This Special Issue focuses on compulsive particles that reflect our understanding of the pathophysiology and treatment of hyponatremia and associated consequences.
Prof. Dr. Lewis S. Blevins
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cerebral salt wasting
- osmotic demyelination
- arginine vasopressin receptor
- arginine vasopressin receptor blockers
- vaptans, tolvaptan